Amsterdam Molecular Therapeutics (AMT) Holding N.V., Annual General Meeting, Sep 12, 2012., at 14:00 Central European Standard Time. Location: Meibergdreef 61, 1105 BA Amsterdam Zuidoost.

Amsterdam Molecular Therapeutics (AMT) Holding N.V. will be removed from Next Biotech Index

Amsterdam Molecular Therapeutics announced data demonstrating that one-time administration of the gene therapy Glybera(R) (alipogene tiparvovec) is able to markedly improve chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal. This results in a much reduced level of newly-formed chylomicrons in the bloodstream, which are considered to be the cause of the acute and recurring bouts of pancreatitis seen in lipoprotein lipase deficiency (LPLD) subjects. LPLD is a very rare inherited condition that is associated with increased levels of chylomicrons. These particles carry certain types of fat in the blood, which because they are not removed from the body can cause recurrent pancreatitis. Data were published online in the Journal of Clinical Endocrinology & Metabolism (JCEM, March, 2012).